Mitazalimab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Mitazalimab (ADC-1013; JNJ-64457107) 是 FcγR 依赖性 CD40 激动剂，具有肿瘤导向活性。Mitazalimab 激活抗原呈递细胞，例如 树突状细胞 (DC)，以启动肿瘤反应性 T 细胞。因此，Mitazalimab 诱导肿瘤特异性 T 细胞浸润并杀死肿瘤。Mitazalimab 可重塑肿瘤浸润性骨髓微环境。

Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment.

——

Animal Model:MB49-tumor bearing mice model Dosage:10, 30, 100 or 300 μg/mouse Administration:Intraperitoneal injection; on day 7, 10 and 13 post-inoculation; sampled at 24 h after final dose Result: Increased the level of IP-10, MIP-1α and TNF-α, but not CXCL1, IFN-γ, IL-6, IL-10, MCP-1 and MIP-2.Resulted in increased frequency of CD44hi CD62L-efector memory CD8+ and CD4+ T cells.

——

Others

Other Targets

Others

——

——

2055640-86-1

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years